Introduction: A Paradigm Shift from Open Surgery to Endoluminal Therapy
For gastroenterologists, pulmonologists, urologists, and interventional endoscopists, the ability to diagnose and treat diseases through natural orifices (mouth, anus, urethra) or small incisions has transformed patient care. Traditional open surgery for gastrointestinal (GI) lesions, respiratory tumors, or urinary obstructions requires large incisions, prolonged hospital stays (5–10 days), significant post-operative pain, and risk of complications (infection, bleeding, herniation). Minimally invasive endoscopic therapeutic devices address these limitations by enabling biopsy, lesion resection, hemostasis, dilation, and stent placement through endoscopic access (gastroscope, colonoscope, bronchoscope, cystoscope, ureteroscope). Benefits include reduced patient trauma, shorter recovery (outpatient or 1–2 day stay), lower complication rates, and improved cosmetic outcomes. As colorectal cancer screening programs expand (polypectomy), GI bleeding incidence rises (aging population, anticoagulant use), and early-stage lung cancer detection increases (bronchoscopic biopsy, ablation), demand for endoscopic therapeutic devices is growing. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Minimally Invasive Endoscopic Therapeutic Device – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Minimally Invasive Endoscopic Therapeutic Device market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hospital endoscopy unit directors, gastroenterology department heads, and surgical procurement managers, the core pain points include achieving hemostasis for acute GI bleeding (peptic ulcers, varices, Mallory-Weiss tears), complete resection of colorectal polyps (adenoma detection rate, piecemeal vs. en bloc), and safe dilation of strictures (benign, malignant). According to QYResearch, the global minimally invasive endoscopic therapeutic device market was valued at US$ 4,813 million in 2025 and is projected to reach US$ 7,753 million by 2032, growing at a CAGR of 7.1% .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095740/minimally-invasive-endoscopic-therapeutic-device
Market Definition and Core Capabilities
Minimally invasive endoscopic therapeutic devices are specialized medical instruments designed to perform diagnostic and therapeutic procedures inside the body using endoscopic access. Core capabilities:
- Biopsy (15–20% of revenue): Forceps (cup, needle, alligator) for tissue sampling (GI, respiratory, urinary). Cold biopsy (small polyps, <5mm) vs. hot biopsy (electrosurgical, coagulation). Used for histopathology (cancer diagnosis, inflammatory bowel disease, celiac disease).
- Hemostasis and Closure (20–25% of revenue, largest segment): Hemostatic clips (through-the-scope, TTS) – mechanical closure of bleeding vessels (ulcers, post-polypectomy). Endoscopic band ligation – variceal bleeding (esophageal varices, gastric varices). Hemostatic sprays (hemospray, TC-325) – diffuse bleeding (malignant ulcers, post-sphincterotomy). Over-the-scope clips (OTSC) – large defects, perforations, fistulas. Endoscopic suturing (Apollo OverStitch) – full-thickness defect closure, bariatric procedures.
- Dilation (10–15% of revenue): Balloon dilators (through-the-scope, wire-guided) for strictures (benign – peptic, anastomotic, Crohn’s; malignant – esophageal, gastric outlet, colonic). Bougie dilators (Savary-Gilliard, Maloney) for esophageal strictures (caustic, radiation, post-surgical).
- EUS (Endoscopic Ultrasound) (10–15% of revenue): EUS-guided fine-needle aspiration (FNA) and fine-needle biopsy (FNB) for pancreatic lesions (cancer, cysts), subepithelial tumors (GIST, leiomyoma), lymph nodes (staging). EUS-guided drainage (cystogastrostomy, choledochoduodenostomy). EUS-guided celiac plexus neurolysis (pain management).
- EMR/ESD (Endoscopic Mucosal Resection / Endoscopic Submucosal Dissection) (15–20% of revenue, fastest-growing at 8–9% CAGR): EMR (snare polypectomy) – large polyps (>20mm), piecemeal resection. ESD (needle knife, IT knife, scissor knife) – en bloc resection of early GI cancers (T1a, high-grade dysplasia, intramucosal cancer). ESD offers higher curative resection rate but longer procedure time, higher perforation risk, and steeper learning curve.
- ERCP (Endoscopic Retrograde Cholangiopancreatography) (10–15% of revenue): Sphincterotome (papillotomy) – biliary and pancreatic sphincterotomy. Stone extraction balloons, baskets – choledocholithiasis (common bile duct stones). Stent placement (plastic, metal) – biliary obstruction (malignant – pancreatic cancer, cholangiocarcinoma; benign – strictures, leaks). Used in gastroenterology (hepatobiliary) and interventional radiology.
Market Segmentation by Application
- Gastroenterology (75–80% of revenue, largest segment): Upper GI (esophagus, stomach, duodenum) – variceal ligation, peptic ulcer hemostasis, esophageal dilation (strictures, achalasia), EMR/ESD (early gastric cancer). Lower GI (colon, rectum) – polypectomy (adenoma, serrated lesions), EMR (large polyps), ESD (early colorectal cancer). ERCP (biliary, pancreatic) – sphincterotomy, stone extraction, stent placement. GI bleeding (ulcers, varices, Mallory-Weiss, Dieulafoy, angiodysplasia, post-polypectomy). Colorectal cancer screening (FIT-positive, diagnostic colonoscopy).
- Respiratory (15–20% of revenue, fastest-growing at 8–9% CAGR): Bronchoscopy – endobronchial biopsy (lung cancer), transbronchial needle aspiration (TBNA, EBUS-TBNA) for lymph node staging. Argon plasma coagulation (APC) – hemoptysis, airway obstruction (tumor debulking). Airway stent placement (tracheal, bronchial) for malignant obstruction (lung cancer, esophageal cancer). Balloon dilation – benign strictures (post-intubation, post-tuberculosis, granulomatosis with polyangiitis, sarcoidosis). Cryotherapy, electrocautery, laser ablation.
- Other (5–10% of revenue): Urology (cystoscopy, ureteroscopy) – bladder tumor resection (TURBT), ureteral stricture dilation, stone extraction. ENT (laryngoscopy, bronchoscopy) – vocal cord biopsy, airway dilation.
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Perforation and bleeding risk during ESD (early GI cancer) and EMR (large polyps) – deep mural injury (muscularis propria) causes perforation (2–10% for ESD, <1% for EMR). Hemostasis (clips, coagulation) essential. Steep learning curve for ESD – requires 50–100 supervised cases for competency. Dedicated training programs (animal models, cadaver labs, simulation) essential for adoption. Scope of practice and reimbursement – ESD is reimbursed in Japan, Korea, China, Europe, and some US centers (investigational). CMS (US) reimburses EMR but not ESD (considered experimental/investigational). Device innovation – new devices (clip closure, hemostatic powders, ESD knives, traction devices) improve safety and efficacy. Robotics (flexible endoscopic robots) under development.
独家观察: EMR/ESD Fastest-Growing Segment for Early GI Cancer Treatment
An original observation from this analysis is the double-digit growth (8–9% CAGR) of EMR/ESD devices for endoscopic resection of early GI cancers (esophageal, gastric, colorectal). Colorectal cancer screening (colonoscopy, FIT) increases detection of early-stage cancers (T1a, high-grade dysplasia, intramucosal cancer). ESD offers en bloc resection (complete removal, accurate pathology staging) vs. piecemeal EMR (fragmentation, risk of residual/recurrence). ESD is standard of care for early GI cancer in Japan, Korea, China, and Europe; adoption in US is slower (reimbursement, training). EMR/ESD segment projected 25%+ of endoscopic therapeutic device market revenue by 2030 (vs. 15% in 2025). Additionally, hemostatic sprays (Hemospray, TC-325) for GI bleeding (malignant ulcers, post-sphincterotomy, diffuse bleeding) are emerging as adjunct to mechanical (clips, bands) and thermal (coagulation) methods. Hemostatic sprays are easy to use (no targeting), cover large surface area, but temporary (wash off). Used for salvage therapy after failed conventional hemostasis.
Strategic Outlook for Industry Stakeholders
For CEOs, product line managers, and medical device investors, the minimally invasive endoscopic therapeutic device market represents a high-growth (7.1% CAGR), technology-driven opportunity anchored by colorectal cancer screening, GI bleeding incidence, and shift to outpatient endoscopy. Key strategies include:
- Investment in ESD knives and traction devices (clip-and-thread, rubber band, magnetic, double-balloon) for en bloc resection of early GI cancers.
- Development of hemostatic sprays and novel clip designs (over-the-scope clips, through-the-scope clips with rotatable jaws) for GI bleeding management.
- Expansion into EUS-guided interventions (drainage, fiducial placement, ablation) for pancreatic and hepatobiliary diseases.
- Geographic expansion into Asia-Pacific (Japan, China, South Korea) for ESD adoption and North America/Europe for EMR and GI bleeding.
Companies that successfully combine device innovation (ESD knives, hemostatic clips, hemostatic sprays), procedural safety, and training support will capture share in a $7.8 billion market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
